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FAKTOR - FAKTOR PROGNOSTIK KEHILANGAN PENGLIHATAN 
SELEPAS PEMBEDAHAN VITREKTOMI DALAM KALANGAN PESAKIT 
DIABETIK RETINOPATI PROLIFERATIF DI HOSPITAL RAJA 
PEREMPUAN ZAINAB II  
 
ABSTRAK 
 
 
Latar belakang kajian: Diabetik Retinopati Proliferatif (DRP) adalah salah satu 
penyebab utama buta di seluruh dunia. Perkembangannya berkait rapat dengan progresif 
retina iskemia daripada diabetik retinopati manakala komplikasinya boleh membawa 
kepada kehilangan penglihatan, saraf retina lekang, dan pendarahan vitreous. Vitrektomi 
adalah asas rawatan apabila komplikasi DRP yang megancam penglihatan mata seperti 
pendarahan vitreous dan saraf retina lekang terjadi. Kajian ini dijalankan bertujuan untuk 
mengenal pasti faktor – faktor prognostik kehilangan penglihatan selepas pembedahan 
vitrektomi dalam kalangan pesakit DRP. Metod: Satu kajian kohot retrospektif, 
melibatkan 164 pesakit DRP yang menjalani pembedahan vitrektomi dari 1 Januari 2012 
hingga 31 Disember 2016 dan mengikuti rawatan susulan di Klinik Oftalmologi Hospital 
Raja Perempuan Zainab II. Nilai ketajaman penglihatan ditentukan dengan mengenal pasti 
garis yang boleh dibaca oleh pesakit berdasarkan carta Snellen. Sudut resolusi minimum 
dan nilai log (LogMar) diperoleh dengan membahagi penyebut dan pengangka daripada 
nilai ketajaman Snellen. Subjek dianggap mengalami kehilangan penglihatan apabila nilai 
ketajaman penglihatan menurun sebanyak 0.3 LogMar selepas pembedahan vitrektomi. 
xvi 
 
Kaplan Meier digunakan untuk menentukan masa median kehilangan penglihatan dan 
Regresi Cox Berkadar Bahaya digunakan untuk mengenal pasti faktor - faktor prognostik 
kehilangan penglihatan. Analisa statistik dibuat menggunakan STATA 14. Dapatan 
kajian: Purata umur pesakit adalah 52.68 tahun (Sisihan Piawai (SP) = 10.32). Pesakit 
terdiri daripada 47.6% lelaki dan 52.4% perempuan. Masa median keseluruhan atau 
median kebarangkalian kehilangan penglihatan yang diperoleh untuk kajian ini adalah 
14.63 bulan  (95% Selang Keyakinan (SK): 11.51, 17.75). Pesakit dengan keadaan pra-
morbid penyakit jantung iskemia (PJI) (Nisbah bahaya terlaras (NB): 1.71, 95% SK: 1.06, 
2.78) dan saraf retina lekang (SRL) pasca pembedahan (NB terlaras: 1.80, 95% SK: 1.16, 
2.79) mempunyai risiko yang lebih tinggi untuk mendapat kehilangan penglihatan pasca 
vitrektomi selepas diselaraskan dengan faktor lain. Kesimpulan: Masa untuk kehilangan 
penglihatan dipengaruhi oleh keadaan pra-morbid PJI dan komplikasi SRL pasca 
pembedahan. Masa median atau durasi survival kehilangan penglihatan adalah lebih 
kurang 14 bulan secara amnya dan ini disarankan agar pesakit perlu dipantau dengan rapi 
sekurang-kurangnya dalam tempoh ini terutamanya kepada pesakit yang mempunyai 
risiko PJI. 
 
Kata kunci: diabetik retinopati proliferatif, kehilangan penglihatan, vitrektomi, PJI, SRL 
pasca pembedahan 
 
 
 
 
xvii 
 
PROGNOSTIC FACTORS OF VISION LOSS AFTER VITRECTOMY 
SURGERY AMONG PATIENTS WITH PROLIFERATIVE DIABETIC 
RETINOPATHY (PDR) IN HOSPITAL RAJA PEREMPUAN ZAINAB II  
 
ABSTRACT 
 
 
Background: Proliferative diabetic retinopathy (PDR) is one of the major cause of 
blindness throughout the world. Its development is primarily related to progressive retinal 
ischemia from diabetic retinopathy while its complications could lead to vision loss, 
tractional retinal detachment, and vitreous hemorrhage. Vitrectomy is the mainstay of 
treatment when sight threatening complications of PDR such as vitreous hemorrhage and 
tractional detachment develop. The aim of this study was to identify the prognostic factors 
of vision loss after vitrectomy surgery among PDR patients. Methods: A retrospective 
cohort study involving 164 patients diagnosed with PDR that underwent vitrectomy 
surgery from 1st January 2012 to 31st December 2016 and were followed up at 
Ophthalmology Clinic Hospital Raja Perempuan Zainab II. Visual acuity values were 
determined by the line that the patients can recognize based on a Snellen chart. The 
Minimum Angle of Resolution and subsequently its log value (LogMar) was obtained by 
dividing the denominator by numerator of the Snellen acuity value. Subjects were 
considered to have vision loss when the visual acuity post vitrectomy surgery dropped by 
0.3 LogMar. Kaplan Meier was used to determine the median time to vision loss and Cox 
Proportional Hazard regression was used to identify the prognostic factors of vision. 
xviii 
 
Statistical analysis was done using STATA 14.  Results:  The mean age of patients was 
52.68 years (SD=10.32). The patients consisted of 47.6% male and 52.4% female. The 
overall median time or median probability of vision loss obtained for this study was 14.63 
months (95% CI:11.51, 17.75). Patients with premorbid condition Ischemic Heart Disease 
(IHD) (Adjusted HR: 1.71, 95% CI: 1.06, 2.78) and post-operative Tractional Retinal 
Detachment (TRD) (Adjusted HR: 1.80, 95% CI: 1.16, 2.79) had a higher risk in having 
vision loss post vitrectomy after adjusting for other factors. Conclusion: Time to vision 
loss was influenced by premorbid condition of IHD and a complication of post-operative 
TRD. Median time or survival duration of vision loss was about 14 months in general and 
this suggest that patients should be followed up closely for at least this period of time, 
especially those with risk factors like IHD. 
 
Keywords: proliferative diabetic retinopathy, vision loss, vitrectomy, IHD, post-
operative TRD 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background of the study 
 
According to the World Health Organization (WHO, 2016), the prevalence of diabetes 
has been rising worldwide, with an increase of almost two-fold over the last two decades. 
The rising trend of diabetes is due to many factors including population growth, aging, 
urbanization and the increasing prevalence of obesity and physical inactivity (Wild et al., 
2004). As the prevalence of diabetes increases, the magnitude of disability secondary to 
diabetic eye disease-related complications likewise will increase (Faudzi et al., 2004). 
While in Malaysia, the prevalence of DR has been estimated to be 39.3% (Abougalambou 
and Abougalambou, 2015).  
 
DR is the most common microvascular complication of diabetes (Mohamed et al., 2007). 
DR will affect nearly all diabetic patients, proportional to the duration of the disease, 
although controlling the blood pressure and blood sugar may delay its onset and the 
progression (Hendrick et al., 2015).  After two decades of disease, almost all Type 1 
diabetic patients will have some degree of retinopathy with more than 80 % insulin-treated 
for Type 2 diabetic patients and 50 % of those not requiring insulin (Romero-Aroca et al., 
2012). Knowing these figures, as well as keeping in mind that diabetic retinopathy is a 
biomarker of the underlying widespread effects of abnormal glucose metabolism on the 
systemic microcirculation (Cheung and Wong, 2008), it is not surprising that patients with 
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diabetic retinopathy represent a major public health concern. The healthcare costs for 
patients with diabetic retinopathy complications are almost double of those without the 
complication, making the societal burden of retinopathy substantial (Heintz et al., 2010).  
 
Chronic diabetes is associated with a multitude of macrovascular and microvascular 
complications, of which retinopathy is only part of the spectrum (Stitt et al., 2016). Some 
studies reported that retinopathy also predicts poorer survival in persons with type 1 
diabetes, but they are associated with concomitant cardiovascular risk factors (Klein et 
al., 1992; Van Hecke et al., 2005). Other potential associations in these patients are 
cerebrovascular disease, heart disease, nephropathy, and systemic vascular complications 
(Cheung and Wong, 2008). Vision loss due to diabetic retinopathy results from several 
mechanisms, including macular oedema, macular ischaemia, and fibrovascular 
contraction secondary to proliferative diabetic retinopathy (Fong et al., 2004). 
 
The rise of morbidity caused by diabetes threatens to overwhelm the stretched healthcare 
system both in developed nations and in the developing world. Based on the National 
Diabetes Statistics Report (2014), as the prevalence of diabetes increase, diabetic 
retinopathy is a major reason of vision impairment affecting approximately 4.2 million 
people in the world. According to Goh (2008), the prevalence of DR in Malaysia from the 
2007 Diabetic Eye Registry was 36.8%. Other than that, the 2007 report on 10,586 
diabetics revealed that 63.3% of eyes examined had no DR, 36.8% had any form of DR, 
of which 7.1% had proliferative diabetic retinopathy while up to 15.0% of eyes had vision 
threatening DR requiring laser or surgery at their first visit (Goh, 2008).  
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Proliferative diabetic retinopathy (PDR) is one of the major cause of blindness in the 
world. According to Danis et al. (2008), its development is primarily related to progressive 
retinal ischemia from diabetic retinopathy, resulting in a compensatory increase of 
angiogenic growth factors and subsequent of abnormal new blood vessels. Vision loss in 
patients with PDR frequently results from complications related to fibrovascular 
proliferation and neovascularization (Fong et al., 1999) and may lead to vision loss, 
tractional retinal detachment, and vitreous hemorrhage. Pars plana vitrectomy is the 
surgery of choice in PDR patients with non-clearing vitreous hemorrhaging, tractional 
retinal detachment (TRD) with or without rhegmategenous retinal detachment, or 
extensive fibrovascular proliferation. In keeping with advancements in vitrectomy 
technique, including microincision surgery, the indicators for surgical intervention are 
now expanding (Gupta and Arevalo, 2013). However, despite the advances in vitrectomy 
techniques and instrumentation, the anatomical and visual outcomes of vitrectomy are still 
unpredictable (Gupta et al., 2012).  
 
Some factors which have been postulated to affect the outcome include pre-operative 
vision in the operated eye and contralateral eye, macular involvement, and the use of 
silicone oil for intraocular tamponade (Yorston et al., 2008). However, many more factors 
which may affect the outcome have yet not been discovered, and the prognosis is 
complicated by the risk of intra-operative and post-operative complications, which may 
necessitate repeat surgery (Gupta et al., 2012, Yorston et al., 2008). For example, Castillo 
et al. (2017) observed that recurrent postoperative vitreous hemorrhaging may occur in a 
significant proportion of patients and delay the visual rehabilitation.  
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According to Thompson (2011), there are also some complications related to vitrectomy 
such as dislocation of cannulas intraoperatively, early postoperative hypotony, choroidal 
detachment, and possibly and increased risk of infectious endophthalmitis. While, in other 
study by Ooto et al. (2008), they stated that the complications can be more severe, causing 
large choroidals or escape of gas with inadequate tamponade in eyes with retinal breaks 
or detachment.  
 
It likely took a few years for retinal surgeons to embrace the new technology of vitrectomy 
because there were initial concerns regarding higher rates of postoperative complications 
with the sutureless vitrectomy surgery (O’Reilly and Beatty, 2007). Diabetic retinopathy 
would be the major public health burden with direct medical costs accounting for $492 
million, in addition to lost time and wages related with receiving care (Saadine et al., 
2008).  
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1.2 Problem statement 
 
Diabetic affect almost all of the 30 or more cell types in the retina (Stitt et al., 2016). 
Although the adverse impact on vision is well recognized, the importance of retinopathy 
signs beyond visual impairment is less well recognized (Frank, 2004). Diabetic vitrectomy 
surgery is a surgical treatment for diabetic retinopathy that has a very high success rate 
for improving vision. Patients with PDR have increased from year to year and undergoing 
vitrectomy is an essential step as a treatment. Data from recent studies showed that patients 
with PDR complications undergoing vitrectomy have a better visual and anatomical 
outcomes and reduced number of complications of vitrectomy compared to those not 
undergoing vitrectomy (Arrigg and Cavallerano, 1998).  
 
Vitrectomy is the mainstay of treatment when sight threatening complications of PDR 
such as vitreous hemorrhage and tractional detachment develop (Korobelnik et al., 2014; 
Massin et al., 2010) Although the majority of vitrectomy surgeries are successful, some 
patients may still lose visual acuity after a successful surgery. Although few studies have 
evaluated factors associated with vision loss after vitrectomy surgery, studies 
investigating the vision loss probability and time to vision loss after vitrectomy among 
patients with PDR are still lacking (Abougalambou and Abougalambou, 2015). 
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1.3 Justification of the study 
 
The ability to directly work on or near the retina holds great promise for the future, not 
only to prevent vision loss, but to restore and enhance the ability to see. Vitrectomy 
surgery is a highly successful treatment for improving vision post complications of 
diabetic retinopathy. However, patients may still experience vision loss post vitrectomy 
surgery. Screening is one of the methods to curb the disease. It allows early detection of 
retinopathy, is essential in order to initiate prompt treatment of sight threatening 
retinopathy, and has been demonstrated to be successfull at in preventing vision loss. 
Providing adequate information to the people about diabetic retinopathy to those affected 
by diabetes and conducting more convenient screening programmes may increase public 
awareness and reduce visual loss (Lewis et al., 2007). 
 
Secondly, to emphasise that although there have been significant advances in the 
treatment, there is still a pressing need for better understanding on the basic mechanisms, 
and timing of vision lost post surgery. This will enable in identifying patients at higher 
risk and to develop timely post-opearative review schedules thus allowing us to intervene 
effectively as soon as or before vision loss occurs. In this study, by identifying factors 
contributing to vision loss after vitrectomy surgery, thus can facilitate intervention 
planning to prevent vision loss post vitrectomy. Besides that, hopefully from the findings 
and results of this study will assist clinicians to provide patients with realistic expectations 
of the visual outcome post vitrectomy surgery.  
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CHAPTER 2 
RESEARCH QUESTIONS, RESEARCH OBJECTIVES AND RESEARCH 
HYPOTHESES 
 
2.1 Research Questions 
 
1. What is the survival duration of vision loss after vitrectomy surgery among 
patients with PDR in HRPZ II? 
2. What are the differences in survival duration of vision loss after vitrectomy surgery 
according to socio-demographic characteristics, clinical characteristics, premorbid 
conditions, and post-operative complications of patients with PDR in HRPZ II? 
3. What are the prognostic factors (socio-demographic characteristics, clinical 
characteristics, premorbid conditions, and post-operative complications) of vision 
loss after vitrectomy surgery among patients with PDR in HRPZ II? 
 
2.2 General Objectives 
 
To determine the survival duration of vision loss and  to identify the prognostics factors 
of vision loss after vitrectomy surgery among patients with PDR in HRPZ II. 
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2.2.1 Specific Objectives 
 
 
1. To determine the survival duration of vision loss after vitrectomy surgery among 
patients with Proliferative Diabetic Retinopathy in HRPZ II.  
2. To determine the differences in survival duration of vision loss after vitrectomy 
surgery according to socio-demographic characteristics, clinical characteristics, 
premorbid conditions, and post-operative complications of patients with PDR in 
HRPZ II.  
3. To identify the prognostic factors (socio-demographic characteristics, clinical 
characteristics, premorbid conditions, and post-operative complications) of vision 
loss after vitrectomy surgery among patients with PDR in HRPZ II. 
 
2.3 Research Hypotheses 
 
1. The survival duration of vision loss after vitrectomy surgery among patients with 
PDR in HRPZ II are different according to socio-demographic characteristics, 
clinical characteristics, premorbid conditions, and post-operative complications. 
2. There are significant association between the prognostic factors (socio-
demographic characteristics, clinical characteristics, premorbid conditions, and 
post-operative complications) with vision loss after vitrectomy surgery among 
patients with PDR in HRPZ II. 
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2.4 Operational Definition  
 
2.4.1  Visual acuity (VA) 
Visual acuity values can be determined by noting the line that the patients can just 
recognise based on a Snellen chart (see Figure 2.1). The Minimum Angle of Resolution 
and subsequently its log value (LogMar) is obtained by dividing the denominator by 
numerator of the Snellen acuity value. (Hajali et al., 2009). For example; VA=6/60 then 
60 was divided by 6 equals to 10 (Log 10 = 1 LogMar). 
 
 
 
 
 
 
 
 
Figure 2. 1: Snellen Chart 
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2.4.2 Vision loss  
Vision loss refers to partial or complete loss of vision. Vision loss also known as vision 
impairment, is a decreased ability to see to the degree that causes problems not fixable by 
the usual means, such as glasses. In this study, subjects were considered to have vision 
loss when the visual acuity post vitrectomy surgery dropped by 0.3 LogMar. This value 
was used because it represents a worsening of the visual acuity by a factor of two, for 
example, a drop from vision of 20/20 to 20/40 on a Snellen acuity chart (Hajali et al., 
2009). 
2.4.3  Pars plana vitrectomy (PPV) 
Pars plana vitrectomy (PPV) is a surgical procedure that involves removal of vitreous gel 
from the eye. The procedure derives its name from the fact that vitreous is removed and 
the instruments are introduced into the eye through the pars plana. 
2.4.4  Proliferative Diabetic Retinopathy (PDR) 
PDR is the more advanced form of diabetic retinopathy. At this stage, circulation problems 
deprive the retina of oxygen. As a result, new fragile blood vessels can begin to grow in 
the retina and into the vitreous, the gel-like fluid that fills the back of the eye. The new 
blood vessels may leak blood into the vitreous, clouding vision. 
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2.4.5  Vitreous Hemorrhage 
VH is the extravasation, or leakage, of blood into the areas in and around the vitreous 
humor of the eye. The vitreous humor is the clear gel that fills the space between the lens 
and the retina of the eye. 
2.4.6  Rhegmatogenous retinal detachment (RRD) 
RRD occur when the retinal detachment develops due to a retinal break. Fluid from the 
vitreous cavity, passes through the retinal break into the potential space under the retina, 
leading to separation of the retina from the underlying choroid. 
2.4.7 Tractional retinal detachment (TRD) 
TRD which occurs due to pre-retinal membrane formation and scarring that pulls the 
retina from its attachment.  
2.4.8  Neovascularization of iris (NVI)  
A medical condition of the iris of the eye in which new abnormal blood vessels (i.e. 
neovascularisation) are found on the surface of the iris. 
2.4.9 Post-operative vitreous hemorrhage (Post-op VH) 
Post-operative or recurrent VH is a common complication occurred after vitrectomy. It 
may occur in association with iris or angle neovascularisation, retinal fibrovascular 
proliferations, or an anterior hyaloidal fibrovascular proliferation. 
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2.4.10 Post-operative tractional retinal detachment (Post-op TRD) 
Occurs due to pre-retinal membrane formation and scarring that pulls the retina from its 
attachment after the vitrectomy surgery. 
2.4.11 Post-operative epiretinal membrane (Post-op ERM) 
An epiretinal membrane is a thin sheet of fibrous tissue that can develop on the surface 
of the macular area of the retina and cause a disturbance in vision. Most epiretinal 
membranes happen because the vitreous (the jelly inside the eye) pulls away from the 
retina. The membrane may also form following eye surgery or inflammation inside the 
eye. 
2.4.12 Post-operative neovascular glaucoma (Post-op NVG) 
Post-operative NVG is defined as neovascularization in the anterior segment and 
intraocular pressure (IOP) ≥ 22 mm Hg after vitrectomy.  
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CHAPTER 3 
LITERATURE REVIEW 
 
3.1 Method of Literature Search 
 
Literature were searched using online databases such as Google Scholar, ScienceDirect, 
PubMed and Scopus for articles from 1980’s to 2017 discussing the prognostic factors of 
vision loss after vitrectomy surgery among patients with PDR. Combinations of the 
following key words were used: prognostic factors, risk factors, diabetic retinopathy, 
proliferative diabetic retinopathy, pars plana vitrectomy, vision loss, tractional retinal 
detachment, rhegmatogenous retinal detachment, vitreous hemorrhage, diabetes, iris 
neovascularization and visual loss. Summaries from the non-English literature were also 
reviewed. 
3.2 Pathophysiology of Diabetic Retinopathy 
 
According to Marques (2015), DR is a common complication of diabetes and is a major 
cause of visual impairment and blindness in many countries. This visual impairment 
results from long-term accumulated damage to the small blood vessels in the retina. 
DR can be defined based on the observation of vascular changes. DR does not cause any 
symptoms, especially if only one eye is affected. Significant causes of blindness from DR 
are diabetic macula edema and proliferative diabetic retinopathy (Hendrick et al., 2015). 
Vascular abnormalities or changes can be recognized by the presence of microaneurysms 
and small hemorrhages, followed by signs of vascular leakage, such as hard exudates and 
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larger hemorrhages, vascular dropout, and neovascularization (Marques, 2015). Based on 
the National Eye Institute (2015) report, diabetic retinopathy may progress through four 
stages; mild non-proliferative retinopathy, moderate non-proliferative retinopathy, severe 
non-proliferative retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). In 
addition, according to Stitt et al. (2016), DR can be very broadly classified into two stages 
which are non-proliferative retinopathy and advanced, proliferative diabetic retinopathy. 
NPDR can be classified into mild, moderate (more than mild but less than severe NPDR) 
and severe. 
 
PDR, the more advanced form of the disease will cause new blood vessels to grow into 
the area of the eye that drains fluid from the eye. This can raise the eye pressure, which 
damages the optic nerve (American Optometric Association, 2017). PDR can cause vision 
loss and even blindness if not treated. According to DOCSHOP (2015), 82% of patients 
that undergoes vitrectomy surgery experience significant improvements in vision after the 
surgery. However, 18% of patients who had vitrectomy complications, 9% have no 
improvement in vision while another 9% experience permanent vision loss. The 
epidemiology of diabetic retinopathy is evolving as prevalence rates increase. Based on a 
survey by National Health and Nutrition Examination Survey (NHANES) 2008, among 
adults over 40 years old, 28 % of people with diabetes have DR and 4 % have vision-
threatening disease.  
 
PDR is indeed the most common form of vision threatening diabetic retinopathy in Type 
1 group patients, but macular edema accounts for most of the vision loss in diabetic 
patients because it is more common in the more prevalent Type 2 group (Lightman and 
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Towler, 2003). In addition, according to Wong et al. 2001, both non-proliferative and 
proliferative diabetic retinopathy have now been related to more severe clinical disease 
such as stroke, coronary heart disease, heart failure and nephropathy. Cheung and Wong 
(2008), stated that diabetic retinopathy also has been long known to be associated with an 
increased risk of mortality and principally due to an increase of cardiovascular disease in 
persons with retinopathy. It is important to note that every patient who develops diabetic 
retinopathy may experience severe vision loss, which generally occurs only in advanced 
stages, due to diabetic macula edema and proliferative diabetic retinopathy (Stitt et al., 
2016).  
3.3 The background of Vitrectomy surgery 
 
Vitrectomy surgery, also known as pars plana vitrectomy (PPV), is a surgical procedure 
that involves removal of vitreous gel from the eye. Pars plana vitrectomy involves the 
introduction of surgical instruments into the eye through the pars plana and can be defined 
as the removal of vitreous (American Academy of Ophthalmology, 2015). PPV was first 
introduced in 1972, when Machemer invented a single port, multifunctional 17-gauge 
cutter called the vitreous infusion suction cutter (VISC) (Machemer et al., 1972). 
According to a study by Diabetic Retinopathy Vitrectomy Study (1985), 25% of patients 
undergoing early PPV regained visual acuity of 20/40 or better compared to 15% of 
patients who underwent conventional treatment.  
 
Based on the study by Ramsay et al. (1986), the duration of significant visual loss prior to 
vitrectomy intervention was less than one month and up to more than six months. The role 
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of pars plana vitrectomy is still unquestionable for managing complications of 
proliferative diabetic retinopathy including those that were previously considered 
blinding. Many favor early vitrectomy as it gives better results and better visual outcomes, 
due to advances in surgical and pharmacologic assisted technique (Gupta et al., 2012). 
PPV is indeed the best option for the patients to treat the complication of proliferative 
diabetic retinopathy. 
 
The first 3-port, 20-gauge vitrectomy system (standard system) in which the sclerotomies 
and conjunctiva were saturated after the procedure was the standard in vitrectomy surgery 
since the mid-1970s and later in 2002, 22-gauge vitrectomy system were introduced 
(Wubben et al., 2016). This was followed by the introduction of a 23-gauge and a 27-
gauge sutureless vitrectomy system (Eckardt et al., 2005; Oshima et al., 2010). Overall, 
there is an increase in the vitrectomy rates per 1000 enrollees over the past decade 
(Wubben et al., 2016). Many of the studies using the small gauge vitrectomy also found 
decrease inflammation and pain postoperatively and improved patients comfort (Kellner 
et al., 2007; Romero et al., 2006). Other studies also reported that small gauge vitrectomy 
has been used successfully for a wide variety of vitreoretinal surgical indications (Tan et 
al., 2008; Spirn et al., 2009). The reduction in the incision size has led to minimization of 
tissue trauma, postoperative convalescence period, less postoperative inflammation, and 
faster recovery (Nagpal et al., 2012). 
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3.4 Median Time or survival duration of Vision Loss 
 
A retrospective study by Gupta et al. (2012) of the patients undergoing PPV from January 
1999 to May 2010 found that out of 249 patients, 95.3% of eyes had a flat retina (retina 
still not functioning properly post-surgery) at final follow-up. According to this study, 
they found that the median time was 14 months with mean 1.44 (SD:1.88 years). 
According to Rice et al. (1983), the cumulative incidence of neovascular glaucoma (NVG) 
occurred in the first few months after vitrectomy with a median time of six months. The 
estimated relative risk of neovascular glaucoma for eyes underwent vitrectomy was 4.6 
with a 95% CI from 1.5 to 13.7.  
 
The post-operative complications primarily occurred the first year after surgery. The most 
frequent postoperative complication was vitreous hemorrhage and tractional retinal 
detachment. For VH, the median probability time was estimated to be in three months 
after vitrectomy for visual acuity less than 0.1 LogMar unit pre-operatively of operated 
eye (Ostri et al., 2014). Other than that, this study also determined the median probability 
time of vision loss for prognostic factor post- operative TRD was 12 months (including 
use of silicone oil in surgey). However, there was no significance difference in risk of 
operated eye for post op TRD (P-value=0.07) with median time was 5.6 months and mean 
time was 10.5 months (SD:19.2 months) (Hwang et al., 2013). 
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3.5 Prognostic factors of vision loss after vitrectomy surgery 
3.5.1 Socio-demographics and clinical characteristics 
 
Most patients who develop severe vision loss after vitrectomy have proliferative diabetic 
retinopathy (Davis et al., 1998). Based on the study by Ramsay et al. (1986), the duration 
of significant vision loss prior to vitrectomy intervention was less than one month and 
would differ according to each patient which some will have vision loss in one to three 
months, three to six months, and more than six months. DR represents a major 
socioeconomic status problem with around 2% of diabetic patients becomes legally blind 
while 10% have a severe visual handicap because of PDR, despite the availability of 
several effective therapeutic treatment such as laser photocoagulation or vitrectomy 
(Zhang et al., 2009).  
 
The incidence of vision loss or blindness increase significantly with age in both younger 
and older onset in taking insulin group. This trend approaches significance with P-value 
= 0.051 in the older onset group not taking insulin. The vision loss was associated with 
age (younger onset: P<0.001, older onset: P<0.001). The rate of blindness increases 
significantly only in the younger onset group when the duration increase (Moss et al., 
1988). However, according to Moss et al. (1988), both not significant in older onset and 
younger onset with p = 0.26 and p = 0.81 respectively. Longer in duration of diabetes and 
more severe retinopathy were associated with the development of proliferative diabetic 
retinopathy in younger group. Because of the presence of PDR, it was associated with an 
increased 4-year risk of loss of vision, cardiovascular disease, diabetic nephropathy, and 
mortality (Klein et al., 1992). In another report by Moss et al, (1988), with the increasing 
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in duration of diabetes, increased the blindness in younger onset persons and older onset 
persons taking insulin.  
 
The rate of occurrence of visual loss after vitrectomy tended to be higher in higher in 
persons 50 years of age or older in person with Type 2 diabetes, in women, visual acuity 
impairment, and macular edema (Davis et al., 1998). The results were estimated using 
multivariate discrete Cox models, proving that baseline visual acuity remained a 
significant factor with odds ratios were approximately 1.5 and 2 or more. Univariate 
models were constructed in which older age, female gender, type 2 diabetes, decreased 
visual acuity, and macular edema were all nominally significant risk factors, and increased 
body weight was of borderline significance (Davis et al., 1998).  
 
Type 1 DM is characterised by beta cell destruction caused by an autoimmune process, 
leading to absolute insulin deficiency while most individuals with type 2 DM exhibit intra-
abdominal obesity which related to the presence of insulin resistance (Baynest, 2015). 
This is the most common form of DM and highly associated with a family history of 
diabetes, older age, obesity and is also common in women (Massin, 2001). Insulin is the 
mainstay of treatment for Type 1 patients. For Type 2 patients, when blood glucose levels 
cannot be controlled by diet, weight loss and oral medications, insulin is also crucial 
(Valera Mora et al., 2003). In contrast, based on the study by Zhang et al. (2009), they 
hypothesized that long-term insulin therapy maybe deteriorates PDR. This is because 
when insulin contacts with retinal vascular endothelium and stimulate VEGF and other 
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growth factor, it will increase retinal vascular permeability resulting in more serious 
retinal edema.  
 
Central vision may be impaired by macular edema or capillary nonperfusion. New blood 
vessels of PDR and contraction of the accompanying fibrous tissue can distort the retina 
and lead to tractional retinal detachment that can produce severe and often irreversible 
vison loss. Moreover, the new blood vessels also can cause bleeding, adding the further 
complication of pre-retinal or vitreous hemorrhage (Fong et al., 2004). According to El 
Annan and Carvounis (2014), diabetic VH secondary to PDR is a cause of severe vision 
loss in diabetic patients. Combined tractional and rhegmatogenous retinal detachment 
(combined RD) is a rare but serious complication in PDR and most of cases undergoing 
PPV for complications of diabetic retinopathy had pre-operative combined RD (Hsu et al., 
2014). Pre-operative neovascularization of the iris (NVI) or also known as rubeosis iridis 
can cause neovascular glaucoma which is a severe ocular complication of PDR 
(Fernandez‐Vigo et al., 1997). While according to Mishra et al. (2013), NVG is a severe 
form of glaucoma characterized by iris neovascularization, a closed anterior chamber 
angle, and extremely high intraocular pressures (IOP) along with severe ocular pain and 
poor vision. 
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3.5.2 Premorbid condition 
 
Losing 3 lines in visual acuity is an important event and would mean that one with initially 
normal vision would have difficulty with small print or figures. This related to 
hypertension in which the proportion of patients who lost this degree of visual acuity was 
significantly higher in the less tight BP control group (higher blood pressure) compared 
with the tightly controlled BP group (lower blood pressure) (Matthews et al., 2004). 
Hypertension is also a major risk factor for the development of other retinal vascular 
diseases, such as retinal vein and artery occlusion. Based on the study of randomised 
clinical trial, adequate controlled of blood pressure can reduce vision loss associated with 
diabetic retinopathy (Wong and Mitchell, 2007). PDR was associated with the incidence 
of stroke mortality in both Type 1 and Type 2 diabetes independent of diabetes duration, 
glycemic control, and other risk factors (Klein et al., 2004). 
 
Risk of heart disease increase as increased in total cholesterol (P < 0.001), LDLC (P = 
0.04), and triglyceride (P = 0.001) levels that were associated with a more rapid onset of 
obvious retinal hard exudate. Patients were at a higher risk of losing visual acuity with the 
extent of hard exudate even after adjusting for the extent of macular edema (Chew et al., 
1996). However, according to Greenberg et al. (2016), the relationships between vision 
loss and future stroke/myocardial infarction (adjusted HR 1.51, 95% CI 0.78–2.90) were 
no longer significant.  
 
22 
 
A study shows that compared to patients without diabetic retinopathy, patients with 
retinopathy are more likely to sustain major adverse cardiac events or complications, for 
example; death, myocardial infarction, heart failure even after factoring effects of age, 
gender, diabetes duration, insulin use, and other factors that may affect prognosis after 
these procedures (Briguori et al., 2005; Ono et al., 2006). Eyes with advanced 
microvascular disease may be particularly susceptible to decreasing in perfusion, leading 
to worsening or macular ischemia and this explained postoperative vision loss in patients 
with diabetic retinopathy (Jain et al., 2012).  
 
The results show the association of chronic kidney disease (CKD) with visual impairment 
(VI), while the odds of VI increased with increasing severity of CKD. In multivariable 
models, CKD was significantly associated with visual impairment with odds ratio = 1.34, 
95% confidence interval (1.14–1.58), and P-value = 0.001 (Wong et al., 2016). Other than 
that, a research by Lin et al. (2014) reported that on patients with kidney disease, the 
creatinine level was significantly higher in the study group (which postoperative VA is 
worse than preoperative VA) (4.07 ± 4.15 mg/dL) than in the control group (which 
postoperative VA is better than preoperative VA) (1.23 ± 0.46 mg/dL; p = 0.003). The 
data in this study showed that the patient’s creatinine level was significantly related to the 
outcome of surgery for PDR.         
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3.5.3 Post-operative complications 
                 
The incidence of vision loss was associated with the presence of macular edema, in 
younger onset, p < 0.001 and also in older onset, p < 0.001. Macula edema were thought 
to be sufficient to cause the visual acuity reduction in the absence of other causes (Moss 
et al., 1988). Postoperative vitreous hemorrhage following PPV for PDR has been 
reported in 12% ‑ 63% of cases and may occur within the first few weeks or even months 
later after the surgery (Yang 1998; Novak et al., 1984; Schachat et al., 1983). The study 
by Khutaila et al., (2013), defined the rate of postoperative VH and reoperation after initial 
vitrectomy and examined associated risk factors after 23-gauge PPV in eyes with 
nonclearing VH resulting from PDR. The study also reported that that 32% of eyes 
develop vitreous hemorrhage following 23‑gauge PPV for diabetic retinopathy. 
Postoperative ophthalmic variables associated with a poor outcome in this study included 
persistent or recurrent VH which showing significant relationship with P-value = 0.003 
(Unver et al., 2009).  
 
According to Wang et al. (2014) in his study, vitreous hemorrhage occurred in 14 eyes 
with the incidence of 4.6% after vitrectomy. VH appeared in postoperative after day one 
up to over six months. The cause of postoperative vitreous hemorrhage would be the 
residual neovascular membrane, insufficient photocoagulation range and intensity, 
neovascularszation, and instable blood glucose level. Postoperative problems that 
affecting vision loss specifically recorded included persistent vitreous hemorrhaging 
(present from postoperative day 1 until beyond 90 days) and recurrent vitreous 
hemorrhaging (after an observed period of clearing (Castillo et al., 2017). The surgical 
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management for PDR-related is the most challenging procedures encountered as the 
complication of VH after vitrectomy (PPV) is the most reported as high as 75 % (Tolentino 
et al., 1989). Common complications after vitrectomy include corneal epithelial defects, 
cataract, recurrent VH, iatrogenic retina breaks, rhegmatogeneous retinal detachment and 
neovascular glaucoma (Yorston et al., 2008). 
 
From the study by Unver et al., (2009), eight out of the eyes that developed post-operative 
rubeosis iridis had recurrent retinal rhegmatogenous detachment (RRD), significant with 
p < 0.001 by using logistic regression. Therefore, in univariate analysis, the significant 
factors for a final visual acuity of less than 5/200 were recurrent RRD which produced a 
relative risk of 64.8. 63% of all post vitrectomy patients achieved a final visual acuity of 
20/200 or better. Worsen visual acuity which was the hand motion were in the patients 
with recurrent retinal detachment after unsuccessful vitrectomy at the time of initial 
surgery (Blodi et al., 1992). According to Castillo et al. (2017), recurrent retinal 
detachment was found (development after an observed period of fully attached retina) and 
new retinal detachment have occurred in an eye that did not previously have a retinal 
detachment after the patients undergoing vitrectomy. Recurrent tractional retinal 
detachment (TRD) was also a predictor for poor visual outcome.  
 
By using logistic regression, recurrent TRD reported to be a significant predictor of vision 
loss with P = 0.02 (Unver et al., 2009). Based on the same study by Blodi et al. (1992), 
showed that after vitrectomy, three patients had new retinal detachments within 6 months 
after vitrectomy. In other study, combined traction and rhegmatogenous retinal 
detachment was found in seven of 10 eyes (70%) in the study group (postoperative VA is 
